🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

InSilico Medicine Hong Kong clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with InSilico Medicine Hong Kong as lead sponsor. Synced 26 Sep 2026
6Current trials
6Recruiting now
1Drug in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

InSilico Medicine Hong Kong is the lead sponsor of 6 current clinical trials in our China and USA registers. 6 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are INS018_055. The most-studied condition is Malignant Mesothelioma.

ClinicalTrials.gov trials by status

  • Recruiting6100%

Trials by phase

  • Phase 1/2233%
  • Phase 2233%
  • Phase 1117%
  • Phase 3117%
01

Clinical trials sponsored by InSilico Medicine Hong Kong

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079 · Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
Phase 1/2 Recruiting 2024-12 USA, China
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460 · ClinicalTrials.gov ↗ · Locally Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting 2025-04 USA, China
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
Phase 1 Recruiting 2024-04 China
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
NCT05975983 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Fibrosis (IPF)
Phase 2 Recruiting 2024-02 USA
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Fibrosis
Phase 3 Recruiting 2026-09 China
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
NCT07265570 · ClinicalTrials.gov ↗ · Ulcerative Colitis
Phase 2 Recruiting 2025-12 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in InSilico Medicine Hong Kong trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in InSilico Medicine Hong Kong trials

9 conditions
Malignant Mesothelioma1Metastatic Malignant Solid Tumor1Advanced Solid Tumor1Locally Advanced/Metastatic Solid Tumors1Idiopathic Pulmonary Fibrosis (IPF)1Advanced Solid Tumors1Relapsed/Refractory B-cell Lymphoma1Idiopathic Pulmonary Fibrosis1Ulcerative Colitis1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China55
Clinical trials in USA33

A trial with sites in more than one country appears in each of those registers.

05

Questions about InSilico Medicine Hong Kong trials

How many clinical trials does InSilico Medicine Hong Kong sponsor?

InSilico Medicine Hong Kong is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are InSilico Medicine Hong Kong trials recruiting?

Yes. 6 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is InSilico Medicine Hong Kong testing?

Its current trials name 1 drug or biological as interventions. The most frequent are INS018_055 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.